Medical Device News Magazine

TCI Unveils Revolutionary Weight Loss Formula at SupplySide West 2023 – Human Trials Showcase Remarkable Effectiveness in Just 14 Days!

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

In a groundbreaking debut at the esteemed SupplySide West 2023 event in Las Vegas, TCI introduced its revolutionary weight loss formula, backed by positive results from human clinical trials. This global exhibition, renowned for its focus on natural health ingredients, showcased TCI’s exclusive weight management solution, which promises impressive results in just 14 days. Notably, participants in the trials experienced significant weight reduction, ranging from 4 to 11 pounds, without requiring major changes to their diet or exercise routines.

TCI’s innovation marks a significant step towards addressing the global challenges of obesity and blood sugar issues. The company is now poised to provide a range of weight management supplements for its business-to-business (B-to-B) clients through collaborations in Original Design Manufacturing (ODM) and Contract Development and Manufacturing Organization (CDMO). The natural and potent supplements generated considerable interest from established healthcare brands at the SupplySide West Exhibition.

Underpinning this achievement is TCI’s sophisticated bioresource data mining platform, which took over 4,000 hours from substance discovery to RNA screening and validation. The primary ingredient in TCI’s exclusive weight loss formula demonstrated remarkable appetite-suppressing effects. Human trials revealed an 11.7% reduction in appetite after four weeks of use, with an astounding 80% improvement rate among participants. Furthermore, the primary ingredient proved highly effective in promoting weight and fat loss, resulting in an average weight loss of 2.2 pounds and a 0.4% reduction in trunk body fat percentage. These findings underscore the product’s efficacy in addressing health problems associated with obesity.

TCI adopted the theme “100 Million, You Fit! -the next huge opportunity in the market” for the exhibition, emphasizing its commitment to providing a one-stop global service. By creating high-performance supplement designs and streamlining the supply chain, TCI aims to enable customers to penetrate global markets swiftly. This approach garnered interest from various customer segments, including pharmaceutical, omni-channel retail, e-commerce, and leading enterprises worldwide.

Obesity remains a pressing global health concern, with the World Obesity Federation projecting potential economic impacts exceeding $4 trillion by 2035. TCI’s innovative technology represents a proactive response to this challenge and offers consumers a natural and powerful weight management solution. The company’s strides are expected to drive a transformative shift in the health industry’s approach to combating obesity.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”